Eyepoint Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Eyepoint Pharmaceuticals
EYPT Stock  USD 16.86  0.57  3.27%   
Analyzing historical trends in various income statement and balance sheet accounts from Eyepoint Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Eyepoint Pharmaceuticals' valuation are summarized below:
Gross Profit
-161.4 M
Market Capitalization
1.4 B
Enterprise Value Revenue
29.6486
Revenue
42.3 M
Earnings Share
(3.09)
There are currently one hundred twenty fundamental signals for Eyepoint Pharmaceuticals that can be evaluated and compared over time across rivals. All traders should verify Eyepoint Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 66 M in 2026. Enterprise Value is likely to drop to about 47.5 M in 2026

Eyepoint Pharmaceuticals Total Revenue

52.25 Million

Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 15.3 K or Total Revenue of 52.3 M, as well as many indicators such as Price To Sales Ratio of 10.59, Dividend Yield of 0.0 or PTB Ratio of 1.36. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Eyepoint Stock
Check out the analysis of Eyepoint Pharmaceuticals Correlation against competitors.
For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.

Eyepoint Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets505.3 M481.2 M155 M
Slightly volatile
Short and Long Term Debt Total26.5 M25.1 M23.5 M
Slightly volatile
Other Current Liabilities23.6 M22.5 M9.2 M
Slightly volatile
Total Current Liabilities59.2 M56.4 M21.3 M
Slightly volatile
Total Stockholder Equity406.3 M387 M108.9 M
Slightly volatile
Property Plant And Equipment Net35.2 M33.6 M7.5 M
Slightly volatile
Cash120.4 M114.7 M64.1 M
Slightly volatile
Non Current Assets Total19.3 M31.6 M15.5 M
Slightly volatile
Non Currrent Assets Other7.2 M6.9 M1.3 M
Slightly volatile
Cash And Short Term Investments447.9 M426.5 M128.3 M
Slightly volatile
Net Receivables663.1 K698 K3.6 M
Slightly volatile
Common Stock Total Equity29.1 K30.6 K398.3 K
Slightly volatile
Liabilities And Stockholders Equity505.3 M481.2 M155 M
Slightly volatile
Other Current Assets11.4 M10.9 M4.2 M
Slightly volatile
Other Stockholder Equity1.5 B1.4 B590.5 M
Slightly volatile
Total Liabilities99 M94.3 M46.1 M
Slightly volatile
Property Plant And Equipment Gross40.1 M38.2 M8.3 M
Slightly volatile
Total Current Assets462.8 M440.8 M137.6 M
Slightly volatile
Intangible Assets17.4 M20.5 M14.8 M
Slightly volatile
Common Stock74.3 K78.2 K155.1 M
Slightly volatile
Common Stock Shares Outstanding68 M64.7 M22.5 M
Slightly volatile
Accounts Payable14.2 M13.5 M4.8 M
Slightly volatile
Other Assets192.9 K172.5 K199.7 K
Pretty Stable
Accumulated Other Comprehensive Income1.1 M925.2 K886.7 K
Pretty Stable
Property Plant Equipment1.3 M1.2 M729 K
Slightly volatile
Current Deferred Revenue15.2 M16 M162.7 M
Slightly volatile
Short Term Debt1.1 M1.1 M164.6 M
Slightly volatile
Other Liabilities8.6 M16.3 M9.5 M
Slightly volatile
Capital Surpluse467 M881.9 M484.8 M
Slightly volatile
Deferred Long Term Liabilities9.8 M15.6 M10.4 M
Slightly volatile
Net Invested Capital406.3 M387 M120.2 M
Slightly volatile
Net Working Capital403.6 M384.4 M115.9 M
Slightly volatile
Long Term Debt Total34.1 M33.7 M25.5 M
Slightly volatile
Short and Long Term Debt11.1 M9.4 M13.7 M
Slightly volatile
Capital Lease Obligations26.4 M25.1 M7.3 M
Slightly volatile
Capital Stock41.6 K61.2 K82.1 K
Slightly volatile

Eyepoint Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M1.4 M1.7 M
Very volatile
Total Revenue52.3 M49.8 M22.2 M
Slightly volatile
Other Operating Expenses228.4 M217.5 M75.9 M
Slightly volatile
Research Development160.5 M152.9 M41.9 M
Slightly volatile
Total Operating Expenses223.9 M213.2 M73.4 M
Slightly volatile
Selling General Administrative63.2 M60.2 M22.8 M
Slightly volatile
Cost Of Revenue3.2 M3.3 M8.7 M
Slightly volatile
Selling And Marketing Expenses143.1 K150.7 K7.8 M
Slightly volatile
Interest Income18.2 M17.4 M4.8 M
Slightly volatile
Reconciled Depreciation2 M1.8 M1.5 M
Slightly volatile

Eyepoint Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow339.8 M323.6 M84.8 M
Slightly volatile
Depreciation1.8 M1.4 M1.6 M
Pretty Stable
Capital Expenditures4.9 M4.7 M1.3 M
Slightly volatile
End Period Cash Flow120.6 M114.8 M64.1 M
Slightly volatile
Change To Netincome46.3 M44.1 M20.5 M
Slightly volatile
Issuance Of Capital Stock144.3 M187.8 M77.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.5911.151.9 K
Slightly volatile
PTB Ratio1.361.4313.7328
Slightly volatile
Days Sales Outstanding5.595.8989.7354
Slightly volatile
Book Value Per Share6.536.874.5608
Pretty Stable
Average Payables2.8 M3.2 M3.5 M
Slightly volatile
Stock Based Compensation To Revenue0.80.760.52
Very volatile
Capex To Depreciation2.492.371.0296
Slightly volatile
PB Ratio1.361.4313.7328
Slightly volatile
EV To Sales8.629.08450
Slightly volatile
Payables Turnover0.350.364.7739
Slightly volatile
Sales General And Administrative To Revenue2.241.392.0323
Slightly volatile
Research And Ddevelopement To Revenue6.183.532.7318
Very volatile
Capex To Revenue0.10.110.0762
Slightly volatile
Cash Per Share5.145.935.6418
Very volatile
Days Payables Outstanding1.1 K1 K586
Pretty Stable
Intangibles To Total Assets0.09440.09930.1891
Slightly volatile
Current Ratio5.958.996.1474
Very volatile
Receivables Turnover67.3764.1622.3086
Slightly volatile
Shareholders Equity Per Share6.536.874.555
Pretty Stable
Debt To Equity0.0710.07471.4461
Pretty Stable
Capex Per Share0.07860.08280.0559
Very volatile
Average Receivables857.7 K1.4 M1.4 M
Very volatile
Revenue Per Share0.840.881.6991
Pretty Stable
Interest Debt Per Share0.420.452.2443
Very volatile
Debt To Assets0.05710.06010.4856
Slightly volatile
Graham Number34.9322.6122.1565
Very volatile
Price Book Value Ratio1.361.4313.7328
Slightly volatile
Days Of Payables Outstanding1.1 K1 K586
Pretty Stable
Ebt Per Ebit1.381.031.1286
Very volatile
Company Equity Multiplier1.681.122.8087
Very volatile
Long Term Debt To Capitalization0.320.210.4579
Slightly volatile
Total Debt To Capitalization0.06660.07010.4199
Slightly volatile
Debt Equity Ratio0.0710.07471.4461
Pretty Stable
Quick Ratio5.978.936.1307
Very volatile
Net Income Per E B T0.710.90.9464
Pretty Stable
Cash Ratio4.362.343.8884
Slightly volatile
Days Of Sales Outstanding5.595.8989.7354
Slightly volatile
Price To Book Ratio1.361.4313.7328
Slightly volatile
Fixed Asset Turnover1.621.7112.0805
Slightly volatile
Debt Ratio0.05710.06010.4856
Slightly volatile
Price Sales Ratio10.5911.151.9 K
Slightly volatile
Asset Turnover0.150.09310.2099
Pretty Stable
Price Fair Value1.361.4313.7328
Slightly volatile

Eyepoint Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap66 M69.5 M1 B
Slightly volatile
Enterprise Value47.5 M54.8 M64.9 M
Slightly volatile

Eyepoint Fundamental Market Drivers

Eyepoint Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Eyepoint Pharmaceuticals Financial Statements

Eyepoint Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Eyepoint Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Eyepoint Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Eyepoint Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue16 M15.2 M
Total Revenue49.8 M52.3 M
Cost Of Revenue3.3 M3.2 M
Stock Based Compensation To Revenue 0.76  0.80 
Sales General And Administrative To Revenue 1.39  2.24 
Research And Ddevelopement To Revenue 3.53  6.18 
Capex To Revenue 0.11  0.10 
Revenue Per Share 0.88  0.84 
Ebit Per Revenue(3.03)(3.19)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY